Related Experiment Videos
Sorting out the evidence on natriuretic peptides.
Peter A McCullough1, Keisha R Sandberg
1Divisions of Cardiology, Nutrition, and Preventive Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA.
Reviews in Cardiovascular Medicine
|October 18, 2003
Summary
B-type natriuretic peptide (BNP) and NT-proBNP are vital biomarkers for diagnosing and assessing heart failure (HF). Their clinical utility is influenced by factors like renal function and plasma half-life.
Area of Science:
- Biochemistry
- Cardiology
- Clinical Diagnostics
Background:
- B-type natriuretic peptide (BNP) is a cardiac neurohormone produced during ventricular myocyte stretch.
- BNP and N-terminal-proBNP (NT-proBNP) are released and cleaved from pre-proBNP.
- Blood measurements of these peptides are established tools in heart failure (HF) management.
Purpose of the Study:
- To review the literature on the clinical applications of BNP and NT-proBNP.
- To discuss the interpretation of these biomarkers in various clinical scenarios.
- To highlight key considerations for their use in patient care.
Main Methods:
- Literature review of studies utilizing BNP and NT-proBNP assays.
- Analysis of clinical data regarding diagnostic and prognostic utility.
- Examination of factors affecting peptide levels and interpretation.
Main Results:
- BNP levels <100 pg/mL generally exclude acute decompensated HF.
- NT-proBNP is valuable in diagnosing HF, assessing severity, and predicting outcomes, especially without renal dysfunction.
- Both peptides have roles in managing acute coronary syndromes (ACS).
Conclusions:
- BNP and NT-proBNP are essential biomarkers in cardiology.
- Understanding their pharmacokinetic properties and clinical context is crucial for accurate interpretation.
- These peptides aid in HF diagnosis, prognosis, and management of related cardiovascular conditions.